ALXO logo

ALX Oncology Holdings Inc.

ALXO
Healthcare|Biotechnology|US
$1.16
+0.01 (+0.43%)
DCF Value
$0.13
Tangible Book / Share
$1.00
Cash / Share
$1.02
Next Earnings Report
Mar 11, 2027
EPS est. -$0.13
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Jan 30, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (3)

Jun 2027
Est. completion
P1NSCLC (Advanced Non-small Cell Lung Cancer)
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091n=170
Dec 2027
Est. completion
P2Breast Cancer, Metastatic
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559n=120
Dec 2030
Est. completion
P1P2HER2-positive Breast Cancer
PRE-ISPY Phase I/II Oncology Platform Program
NCT05868226n=280

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Apr 2026
P2
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
NCT05467670
Mar 2025
P2
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
NCT04675333
Mar 2025
P2
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
NCT04675294

Recent Press Releases

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Sep 28, 2026 · GlobeNewsWire
ALX Oncology to Present at Upcoming Investor Conferences in September
Sep 2, 2026 · GlobeNewsWire

SEC Filings (64)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 16, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Oct 15, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 30, 20268-KMaterial eventDocumentIndex
Jun 26, 20268-KMaterial eventDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
May 27, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 8, 202610-QQuarterly reportDocumentIndex
May 8, 20268-KMaterial eventDocumentIndex
Apr 28, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 20, 2026ARSAnnual report to holdersDocumentIndex
Apr 20, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 13, 20268-KMaterial eventDocumentIndex
Mar 9, 202610-KAnnual reportDocumentIndex
Feb 27, 20268-KMaterial eventDocumentIndex
Feb 9, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 6, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 4, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jan 30, 2026424B5Offering prospectusDocumentIndex
Jan 30, 20268-KMaterial eventDocumentIndex
Jan 30, 20268-KMaterial eventDocumentIndex
Jan 21, 2026S-8Employee stock planDocumentIndex
Jan 21, 20268-KMaterial eventDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 7, 202510-QQuarterly reportDocumentIndex
Nov 7, 20258-KMaterial eventDocumentIndex
Oct 22, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 8, 2025SC 13GPassive 5%+ stakeDocumentIndex
Sep 12, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 202510-QQuarterly reportDocumentIndex
Aug 12, 20258-KMaterial eventDocumentIndex
Jun 12, 20258-KMaterial eventDocumentIndex
May 15, 2025SC 13G/APassive 5%+ stakeDocumentIndex